Aethlon Medical, Inc.

NasdaqCM:AEMD Stock Report

Market Cap: US$3.9m

Aethlon Medical Management

Management criteria checks 2/4

Aethlon Medical's CEO is Jim Frakes, appointed in Jan 2008, has a tenure of 16.25 years. directly owns 0.009% of the company’s shares, worth $356.04. The average tenure of the management team and the board of directors is 2.2 years and 6.4 years respectively.

Key information

Jim Frakes

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure16.3yrs
CEO ownership0.009%
Management average tenure2.2yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aug 02
We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Jul 11

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Mar 18
We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Nov 09
We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Aethlon Medical climbs on Reddit interest

Jun 09

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

May 12
We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

We're Hopeful That Aethlon Medical (NASDAQ:AEMD) Will Use Its Cash Wisely

Jan 27
We're Hopeful That Aethlon Medical (NASDAQ:AEMD) Will Use Its Cash Wisely

Aethlon Medical has a new business and medical chief

Jan 06

Aethlon Medical (AEMD) rockets 63% as FDA amends Hemopurifier IDE for COVID-10 treatment

Dec 16

Aethlon names Charles J. Fisher, Jr., M.D. as CEO

Nov 03

CEO Compensation Analysis

How has Jim Frakes's remuneration changed compared to Aethlon Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$12m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022n/an/a

-US$13m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021n/an/a

-US$9m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021US$582kUS$275k

-US$8m

Dec 31 2020n/an/a

-US$7m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020US$355kUS$264k

-US$6m

Dec 31 2019n/an/a

-US$6m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019US$286kUS$256k

-US$6m

Dec 31 2018n/an/a

-US$6m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018US$235kUS$235k

-US$6m

Compensation vs Market: Insufficient data to establish whether Jim's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Frakes (66 yo)

16.3yrs

Tenure

US$581,661

Compensation

Mr. James B. Frakes, also known as Jim, M.B.A. has been the Chief Financial Officer at Aethlon Medical, Inc. since January 2008 and serves as its Interim Chief Executive Officer and Director since November...

Leadership Team

NamePositionTenureCompensationOwnership
Guy Cipriani
Chief Operating Officerless than a yearUS$347.50k0.068%
$ 2.7k
Steven LaRosa
Chief Medical Officer3.3yrsUS$430.00k0%
$ 0
James Frakes
Interim CEO16.3yrsUS$581.66k0.0090%
$ 356.0
Lee Arnold
Chief Scientific Officer1.2yrsno datano data

2.2yrs

Average Tenure

59.5yo

Average Age

Experienced Management: AEMD's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Frakes
Interim CEOless than a yearUS$581.66k0.0090%
$ 356.0
Edward Broenniman
Independent Chairman of the Board25.1yrsUS$147.50k0.48%
$ 18.9k
Nathan Levin
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Gregory T. Kovacs
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Claudio Ronco
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Larry Cowgill
Member of Sepsis & Inflammation Advisory Boardno datano datano data
Charles Fisher
Member of Extracorporeal Therapy Advisory Boardno dataUS$460.00k0.075%
$ 2.9k
John Kellum
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Chetan Shah
Independent Director10.8yrsUS$117.50k0.44%
$ 17.5k
David Ward
Member of Extracorporeal Therapy Advisory Boardno datano datano data
Irshad Chaudry
Member of Sepsis & Inflammation Advisory Boardno datano datano data
Angela Rossetti
Independent Director2yrsUS$138.00k6.4%
$ 252.0k

6.4yrs

Average Tenure

70yo

Average Age

Experienced Board: AEMD's board of directors are considered experienced (6.4 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.